Catalog No.
DHC35101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG4-nd
Clonality
Monoclonal
Target
CD49 antigen-like family member E, Integrin alpha-F, ITGA5, VLA-5, Fibronectin receptor subunit alpha, CD49e, Integrin alpha-5, FNRA
Concentration
3.79 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08648
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 558480-40-3
Clone ID
Volociximab
Volociximab in cancer, PMID: 22192080
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study, PMID: 19047123
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits, PMID: 17786386
Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer, PMID: 22904239
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer, PMID: 21276608
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent, PMID: 17024968
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients, PMID: 19468731
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo, PMID: 18042290
Protein-driven mechanism of multiorgan damage in COVID-19, PMID: 33103107
β1-integrin: a potential therapeutic target in the battle against cancer recurrence, PMID: 21900388
Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody, PMID: 17330407
Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment, PMID: 23782133
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives, PMID: 26675567
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review, PMID: 28698469
Novel drugs for renal cell carcinoma, PMID: 18808310
Gateways to clinical trials, PMID: 17805439
Gateways to clinical trials, PMID: 19798455
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions, PMID: 33420367
Gateways to clinical trials, PMID: 19907722
Gateways to clinical trials, PMID: 19557204
Gateways to clinical trials, PMID: 17136234
Membrane proteome analysis of glioblastoma cell invasion, PMID: 25853691
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions, PMID: 21789125
Combination therapy for age-related macular degeneration, PMID: 19553801
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy, PMID: 17997441
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008, PMID: 18326919
Integrins as target: first phase III trial launches, but questions remain, PMID: 20460633
[Report of the 10th Annual Meeting of the Chinese society of Clinical Oncology], PMID: 18334158
For research use only. Not for human or drug use.
